ArticleGene therapy2014
Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs.
Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.Oncotarget · 2016Trial
- Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus.Molecular therapy oncolytics · 2018Article
- A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic Colorectal Cancer Model.Molecular imaging and biology · 2018Article
- Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis.Cancer investigation · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic adenoviruses (Ad) represent a promising therapeutic platform for the treatment of cancer. Despite their reliable safety and ease of handling, the recognized oncolytic Ad immune responses, biodistribution, spreads and efficacy of viral replication, compared with non-replicating adenoviruses, in vivo, have not been well understood. The present study establishes a novel permissive mouse immunocompetent orthotopic colon carcinoma model focusing on non-replicating Adv-TKs, a well-established adjuvant treatment in cancer and comparing its antitumor efficacy and safety profile with those of the two newly synthesized oncolytic Ad vectors, M7 and M8, formed by the insertion of a fragment of HSV-TK cDNA into the deleted 6.7 K/gp19 K or ADP in the E3 region to the E1A CR2-deleted Ad5 vectors. Systemic administration in the permissive immunocompetent orthotopic colon carcinoma mouse model, which could better predict the clinical results of Ad-based treatment by combining the characteristics that fully mimic the clinical orthotopic carcinogenesis and permissive Ad replication, show M7 and M8, especially M8, to have more powerful antitumoral efficacy and similar safety profiles relative to the Adv-TK. This promises a significant advance in the field of Ad cancer therapy and will perhaps provide the impetus to design new preclinical M7 and M8 viruses in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.